Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

Journal of Immunology

Volumn 164, Issue 8, 2000, Pages 4178-4184

  Idusogie, Esohe E ^a   Presta, Leonard G ^a   Gazzano Santoro, Helene ^a   Totpal, Klara ^a   Wong, Pin Yee ^a   Ultsch, Mark ^a   Meng, Y Gloria ^a   Mulkerrin, Michael G ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CHIMERIC ANTIBODY; IMMUNOGLOBULIN G1; RITUXIMAB;

AMINO ACID SUBSTITUTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BINDING AFFINITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG BINDING SITE; HUMAN; NONHUMAN; PRIORITY JOURNAL;

EID: 0034655265     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.8.4178     Document Type: Article

References (27)

1. Reff, M. E., K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. Newman, N. Hanna, and D. R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435.
2. Shan, D., J. A. Ledbetter, and O. W. Press. 1998. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644.
3. Hughes-Jones, N. C, and B. Gardner. 1979. Reaction between the isolated subunits of lhe complement component C1q and IgG-complexes. Mol. Immunol. 16:697.
4. Cooper, N. R. 1985. The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol. 37:151.
5. Ward, E. S., and V. Ghetie. 1995. The effector functions of immunoglobulins: implications for therapy. Ther. Immunol. 2:77.
6. Burton, D. R., J. Boyd, A. D. Brampton, S. B. Easterbrook-Smith, E. J. Emanu, J. Novotny, T. W. Rademacher, M. R. van Schravendijk, M. J. E. Sternberg, and R. A. Dwek. 1980. The C1q receptor site on immunoglobin G. Nature 288:338.
7. Duncan, A. R., and G. Winter. 1988. The binding site for C1q on IgG. Nature 332:738.
8. H2 Domain. J. Exp. Med. 173:1025.
9. Brekke, O. H., T. E. Michaelsen, A. Aase, R. H. Sandin, and I. Sandlie. 1994. Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis. Eur. J. Immunol. 24:2542.
10. H2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRI and FcγRIII binding. Immunology 86:319.
11. Tao, M. H., and S. L. Morrison. 1989. Studies of aglycosylated chimeric mouse-human IgG: role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143:2595.
12. H2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J. Exp. Med. 180:1087.
13. Lund, J., N. Takahashi, J. D. Pound, M. Goodall, and R. Jefferis. 1996. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fcγ receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol. 157:4963.
14. White, K. D., R. D. Cummings, and F. J. Waxman. 1997. Ig N-glycan orientation can influence interactions with the complement system. J. Immunol. 158:426.
15. Tao, M. H., R. I. F. Smith, and S. L. Morrison. 1993. Structural features of human immunoglobin G that determine isotype-specific differences in complement activation. J. Exp. Med. 178:661.
16. H2 domains contributes to their differential ability to bind and activate complement. J. Biol. Chem. 269:3469.
17. Ghetie, V., and E. S. Ward. 1995. Genetic manipulation of antibodies: from variable domains to constant regions. Adv. Antibody Engineering 1:169.
18. Kim, J. K., M. F. Tsen, V. Ghetie, and E. S. Ward. 1994. Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur. J. Immunol. 24:2429.
19. Eaton, D. L., W. I. Wood, D. Eaton, P. E. Hass, P. Hollingshead, K. Wion, J. Mather, R. M. Lawn, G. A. Vehar, and C. Gorman. 1986. Construction and characterization of an active factor VIII variant lacking the central one third of the molecule. Biochemistry 25:8343.
20. Kunkel, T. A. 1985. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc. Natl. Acad. Sci. USA 82:488.
21. Gorman, C. M., D. R. Gies, and G. McCray. 1990. Transient production of proteins using an adenovirus transformed cell line. DNA Protein Eng. Techniques. 2:3.
22. Gazzano-Santoro, H., P. Ralph, T. C. Ryskamp, A. B. Chen, and V. R. Mukku. 1997. A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J. Immunol. Methods 202:163.
23. Sasaki, T., M. Ueda, and K. Yonemasu. 1982. The subcomponent C1q of the first component of guinea pig complement: purification and characterization. J. Immunol. Methods 48:121.
24. Garred, P., T. E. Michaelsen, and A. Aase. 1989. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand. J. Immunol. 30:379.
25. Michaelsen, T. E., P. Garred, and A. Aase. 1991. Human IgG subclass patter of inducing C.-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and C. concentration. Eur. J. Immunol. 21:11.
26. Brekke, O. H., T. E. Michaelsen, and I. Sandlie. 1995. The structural requirements for complement activation by IgG: does it hinge on the hinge. Immunol. Today 16:85.
27. Jefferis, R., J. Lund, and J. D. Pound. 1998. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol. Rev. 163:59.